Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pfizer to Develop Market for Sutent as First-Line Therapy for RCC
July 28, 2008
- Clopidogrel May Be Less Effective in Japanese than in Westerners
July 28, 2008
- Eisai Develops Add'l Indications, Dosage Forms for Aricept as Part of Life Cycle Management
July 28, 2008
- Korosho Presents Draft Vision for Medical Devices Industry
July 28, 2008
- Kyowa Hakko, Lonza Extend Their Strategic Collaboration
July 28, 2008
- Use of Tamiflu Not Correlated with Abnormal Behavior: Korosho Working Group
July 21, 2008
- Chuikyo to Conduct Survey to Verify Effects of FY2008 Medical Fee Revision
July 21, 2008
- Switch OTC Drugs Hold Key to Market Revitalization
July 21, 2008
- FPAMJ's Proposal Meets Harsh Opposition at Chuikyo
July 21, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 21, 2008
- Industry Needs to Present More Data on Reform Proposed by It
July 21, 2008
- Korosho's Draft Report Sits on the Fence Re Qualification of Store Managers
July 21, 2008
- NEW PRODUCTS／Daiichi Sankyo, Lead Chemical: Loxonin Tape
July 21, 2008
- New OTC Drug Sales System Ready to Go
July 21, 2008
- BUSINESS NEWS IN BRIEF
July 21, 2008
- GENERICS NEWS IN BRIEF
July 21, 2008
- Takeda Applies for Mutual Agreement Procedure to Resolve Double Taxation
July 21, 2008
- OHARA Aims at Sales of \700 Mil. with Amlodipine Generics in FY2009
July 21, 2008
- Ain Pharmaciez to Achieve 90% Price Agreement Rate by End of July
July 21, 2008
- Korosho Tests Purity of Generics of 10 APIs
July 21, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…